Investor Relations
Company Overview
Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.
Latest News
Jun 18, 2025 • 7:00 AM EDT
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
May 27, 2025 • 10:05 AM EDT
Avalo Therapeutics to Participate in Upcoming Investor Conferences
May 12, 2025 • 7:00 AM EDT
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
Stock Information
Nasdaq: AVTX
Avalo Therapeutics, Inc.
Price
Change
Volume
Day Range
52 Week Range